AbCellera
@AbCelleraBio
Followers
6K
Following
237
Media
229
Statuses
410
AbCellera is clinical-stage biotech company focused developing antibody-based medicines in the areas of endocrinology, women’s health, immunology and oncology
Vancouver, British Columbia
Joined January 2016
AbCellera to Participate at Upcoming Investor Conferences in September.
3
7
93
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms.
10
18
154
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025.
2
12
115
Visit our poster at Antibody Engineering & Therapeutics Europe 2025 to learn how we leverage multiple T-cell engager building blocks to generate molecules with in vivo efficacy. Read more about our TCE platform: #AntibodyEngineering
2
5
56
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575.
6
19
114
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause.
0
11
104
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit.
5
9
83
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting .
0
10
68
Visit our poster at #PEGSSummit to learn how multiple T-cell engager (TCE) building blocks can be leveraged to tailor TCE design for diverse tumor targets. Read more about our TCE platform:
1
1
12
Visit our poster at #SIDSanDiego25 to learn about a novel, fully human and half-life extended anti-OX40L monoclonal antibody that is being developed for the treatment of moderate-to-severe atopic dermatitis. Read more about our pipeline here:
1
2
24
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025.
1
3
52
Visit our poster at #AACR25 to see how combining diverse CD3- and tumor-binding antibodies and empirically testing for optimal combinations can generate T-cell engagers (TCEs) with in vivo efficacy. Read more about our TCE platform here: #ImmunoOncology
1
6
30
Visit our poster at #festivalofbiologics in San Diego to learn how we’re leveraging our T-cell engager (TCE) platform to design and optimize TCEs for solid tumor targets. Read more about our TCE platform:
0
8
29
AbCellera to Participate at Upcoming Investor Conferences in May and June.
1
1
22
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025.
1
3
45
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025.
0
6
65
AbCellera to Participate at Upcoming Investor Conferences in March.
1
0
26
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025.
0
4
33